ArticleMedicine2026
Clinical outcome of pingyangmycin-polidocanol foam versus pingyangmycin alone in pediatric cystic lymphatic malformation with intracapsular hemorrhage: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic lymphatic malformations (CLMs) with intracapsular hemorrhage present a management challenge. This study aimed to describe and compare the clinical outcomes associated with pingyangmycin-polidocanol foam (PPF) versus pingyangmycin (PYM) sclerotherapy in this pediatric population. A retrospective cohort study was conducted on 74 pediatric patients with CLMs and intracapsular hemorrhage treated between October 2020 and May 2023. Patients were treated with either PPF (n = 37) or PYM (n = 37). The primary outcomes were lesion volume reduction grading, number of treatment sessions, pain relief, and family satisfaction. Secondary outcomes included adverse effects and recurrence. Factors associated with treatment response were explored. Baseline characteristics were comparable between groups. Children in the PPF group exhibited a greater median reduction in lesion volume after the first session (23.0 cm3 vs 12.2 cm3, P = .028) and received fewer median treatment sessions (2 vs 3, P = .023) compared with those in the PYM group. A higher proportion in the PPF group achieved a good response (Achauer grade III/IV) after the final treatment (83.8% vs 73.0%, P = .020) and reported complete pain relief (73.6% vs 41.7%, P = .036). Family satisfaction scores were significantly higher in the PPF group (P = .020). There were no significant differences in overall adverse event rates (18.9% vs 27.0%, P = .407) or recurrence rates (21.6% vs 27.0%, P = .787). Multivariable analysis confirmed that PPF treatment and macrocystic/mixed lesion type were independent factors associated with a good response. An increased number of treatment sessions was associated with more adverse effects but lower recurrence. In this retrospective analysis, PPF sclerotherapy was associated with a greater initial volume reduction, fewer treatment sessions, and higher family satisfaction compared with PYM alone in pediatric CLMs with intracapsular hemorrhage. Macrocystic and mixed lesions showed better response to PPF. Prospective studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.